Aprea Therapeutics, Inc.

As of May 16, 2022, Aprea Therapeutics, Inc. was acquired by Atrin Pharmaceuticals LLC, in a reverse merger transaction. Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapeutics that reactivate mutant p53 tumor suppressor protein. The company’s lead product candidate is APR-246, a small molecule p53 reactivator, which is in late-stage clinical development for the treatment of hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML); Phase I clinical trials for the treatment of relapsed/refractory TP53 mutant chronic lymphoid leukemia; and Phase I/II clinical trials in relapsed/refractory gastric, bladder, and non-small cell lung cancers. It also develops APR-548, a p53 reactivator, which is in Phase I clinical trials for the treatment of MDS and AML. The company was founded in 2006 and is headquartered in Boston, Massachusetts.